IG-Pod 50 Dry Syrup contains Cefpodoxime Proxetil equivalent to 50 mg per 5 ml, a third-generation cephalosporin antibiotic with broad-spectrum activity against various Gram-positive and Gram-negative bacteria. It is indicated for the treatment of respiratory tract infections, urinary tract infections, skin and soft tissue infections, and uncomplicated gonorrhea caused by susceptible organisms. Cefpodoxime Proxetil acts by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. The dry syrup formulation is designed for pediatric use, providing an accurate and palatable dosing option. After reconstitution, the suspension should be stored as per guidelines and used within the recommended period to maintain efficacy. Dosage and duration of therapy should be determined based on the severity of infection, patient age, weight, and renal function. Common adverse effects may include gastrointestinal disturbances such as diarrhea, nausea, and abdominal discomfort, while hypersensitivity reactions are rare but possible. Caution is advised in patients with a history of penicillin or cephalosporin allergy. IG-Pod 50 Dry Syrup should be used under medical supervision, ensuring adherence to prescribed dosage to prevent resistance development and optimize therapeutic outcomes.